Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic response to pentoxifylline and its active metabolites in dogs with familial canine dermatomyositis.

Veterinary therapeutics : research in applied veterinary medicine - 1 Jan 2003

Rees Christine A, Boothe Dawn M

Abstract excerpt

Ten dogs diagnosed with familial canine dermatomyositis based on clinical findings and skin biopsy results were treated PO with pentoxifylline (25 mg/kg twice daily) for 3 months. Blood and urine samples were collected biweekly for complete blood counts, serum chemistries, and urinalysis. Additionally, serum was analyzed for pentoxifylline and its two primary metabolites (metabolites 1 [M1] and 5 [M5]); physical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Administration, Oral
Share to Dermatomyositis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Dog Diseases

Share to Genetic Predisposition to Disease

Share to Treatment Outcome

Source

Identifiers

PMID: 15136984

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Therapeutic response to pentoxifylline and its active metabolites in dogs with familial canine dermatomyositis.PMID 15136984Read ↗

Inflammatory phenotype, clinicopathologic variables, and effects of long-term methylene blue in dogs with hereditary methemoglobinemia caused by cytochrome b5 reductase deficiency.Semantic proximity Read ↗

Evaluation of the safety of spinosad and milbemycin 5-oxime orally administered to Collies with the MDR1 gene mutation.Semantic proximity Read ↗

Elucidation of the effects of the CYP1A2 deficiency polymorphism in the metabolism of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-d]pyrimidine-2-(1h)-one (YM-64227), a phosphodiesterase type 4 inhibitor, and its metabolites in dogs.Semantic proximity Read ↗

The canine CYP1A2 deficiency polymorphism dramatically affects the pharmacokinetics of 4-cyclohexyl-1-ethyl-7-methylpyrido[2,3-D]-pyrimidine-2-(1H)-one (YM-64227), a phosphodiesterase type 4 inhibitor.Semantic proximity Read ↗

Modest effect of impaired P-glycoprotein on the plasma concentrations of fexofenadine, quinidine, and loperamide following oral administration in collies.Semantic proximity Read ↗

<span style="mso-bidi-font-weight: bold;">Spontaneous Canine Disease Models in Biomedical Science: A One Health Path to Predictive Drug DevelopmentSemantic proximity Read ↗

Leveraging Canine Disease Models in Pharmaceutical Sciences: A One Health Path to Parallel Drug DevelopmentSemantic proximity Read ↗

Are We Going to the Dogs? Human Disease Phenotypes in CaninesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.